Eli Lilly And Stock Price To Sales
| LILY34 Stock | BRL 165.13 2.32 1.42% |
Eli Lilly and fundamentals help investors to digest information that contributes to Eli Lilly's financial success or failures. It also enables traders to predict the movement of Eli Stock. The fundamental analysis module provides a way to measure Eli Lilly's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eli Lilly stock.
Eli |
Eli Lilly and Company Price To Sales Analysis
Eli Lilly's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Eli Lilly Price To Sales | 60.93 X |
Most of Eli Lilly's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eli Lilly and is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Eli Lilly and has a Price To Sales of 60 times. This is 184.72% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The price to sales for all Brazil stocks is notably lower than that of the firm.
Eli Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eli Lilly's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eli Lilly could also be used in its relative valuation, which is a method of valuing Eli Lilly by comparing valuation metrics of similar companies.Eli Lilly is rated second overall in price to sales category among its peers.
Eli Fundamentals
| Return On Equity | 0.65 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 1.91 T | |||
| Shares Outstanding | 28.51 B | |||
| Price To Earning | 41.09 X | |||
| Price To Book | 34.13 X | |||
| Price To Sales | 60.93 X | |||
| Revenue | 28.54 B | |||
| Gross Profit | 21.91 B | |||
| EBITDA | 8.28 B | |||
| Net Income | 6.24 B | |||
| Cash And Equivalents | 3.06 B | |||
| Cash Per Share | 1.68 X | |||
| Total Debt | 15.35 B | |||
| Debt To Equity | 2.29 % | |||
| Current Ratio | 1.42 X | |||
| Book Value Per Share | 5.59 X | |||
| Cash Flow From Operations | 7.26 B | |||
| Earnings Per Share | 1.16 X | |||
| Price To Earnings To Growth | 2.07 X | |||
| Number Of Employees | 47 | |||
| Beta | 0.35 | |||
| Market Capitalization | 1.82 T | |||
| Total Asset | 48.81 B | |||
| Z Score | 70.8 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 2.11 % | |||
| Net Asset | 48.81 B | |||
| Last Dividend Paid | 3.92 |
About Eli Lilly Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly and's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly and based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Eli Stock
When determining whether Eli Lilly offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.